阿片暴露婴儿的分娩时机
本研究为单中心回顾性队列研究,纳入2010至2017年≥37周分娩的阿片暴露孕妇所生婴儿399例,比较早期足月(37-<39周)、完全足月(39-<41周)和晚期足月(41-<42周)三组新生儿结局。结果显示,主要复合结局、新生儿阿片戒断综合征发生率及其他次要结局(除出生体重外)在三组间无显著差异,提示阿片暴露婴儿可能不会从早期足月分娩中获益。
要点
- 早期足月、完全足月和晚期足月三组的新生儿主要复合结局无显著差异。
- 三组新生儿阿片戒断综合征发生率无显著差异,其他次要结局除出生体重外也无显著差异。
- 阿片暴露新生儿中新生儿阿片戒断综合征和新生儿重症监护病房入住率较高。
核心结论
- 尽管阿片暴露新生儿发病率较高,但早期足月、完全足月和晚期足月分娩的新生儿阿片戒断综合征发生率及严重程度或其他新生儿结局无差异,提示阿片暴露婴儿可能不会从早期足月分娩中获益。
研究设计与样本
- 本研究为单中心回顾性队列研究,纳入2010至2017年≥37周分娩的阿片暴露孕妇所生婴儿399例,排除多胎妊娠或胎儿畸形。
- 孕妇阿片暴露定义为处方(包括药物辅助治疗)或非处方阿片使用,或孕期阿片类尿药筛查阳性。
- 早期足月(37-<39周)、完全足月(39-<41周)和晚期足月(41-<42周)分组依据美国妇产科医师学会定义。
主要发现
- 399例婴儿中,早期足月136例(34.1%)、完全足月229例(57.4%)、晚期足月34例(8.5%)。
- 270例(67.7%)患者因阿片使用障碍接受药物辅助治疗;除鼻吸海洛因史、海洛因或任何阿片类尿毒理学筛查阳性及分娩指征外(P<.05),各组基线特征相似。
- 主要复合结局发生于313例(78.4%)新生儿,296例(74.2%)新生儿发生新生儿阿片戒断综合征。
- 219例(54.9%)阿片暴露新生儿入住新生儿重症监护病房,160例(40.1%)需要药物性新生儿阿片戒断综合征治疗,平均疗程近3周(19.0±16.1天)。
- 早期足月、完全足月和晚期足月三组间主要复合结局、新生儿阿片戒断综合征发生率或其他次要结局(除出生体重外)无显著差异。
关键数值与推荐
- 主要结局为新生儿复合结局:呼吸窘迫综合征、新生儿脓毒症、新生儿惊厥、缺氧缺血性脑病、需治疗的黄疸、5分钟Apgar评分<5、新生儿重症监护病房入住、新生儿阿片戒断综合征或新生儿死亡。
- 次要结局包括主要结局的各个组成部分、出生体重、新生儿阿片戒断综合征治疗需求及疗程、住院时间及最大Finnegan评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of opioid use disorder and medication-assisted treatment in pregnancy is increasing. Compared with term infants, preterm infants have a lower incidence of neonatal opioid withdrawal syndrome. It is unknown whether early term delivery compared with full or late-term delivery decreases the risk of neonatal opioid withdrawal syndrome. OBJECTIVE: This study aimed to compare the neonatal outcomes among opioid-exposed infants born in the early, full, and late-term periods. STUDY DESIGN: This was a retrospective cohort study of opioid-exposed pregnancies delivering at a single center from 2010 to 2017 at ≥37 weeks gestation. Participants with multiple gestations or fetal anomalies were excluded. Maternal opioid exposure was defined as prescription (including medication-assisted treatment) or nonprescription opioid use or a positive urine drug screen in pregnancy for opiates. The primary outcome was a neonatal composite of respiratory distress syndrome, neonatal sepsis, neonatal seizures, hypoxic ischemic encephalopathy, jaundice requiring treatment, 5-minute Apgar <5, neonatal intensive care unit admission, neonatal opioid withdrawal syndrome, or neonatal death. The secondary outcomes included individual components of the primary outcome, birthweight, need for and length of neonatal opioid withdrawal syndrome treatment, length of hospital admission, and maximum Finnegan scores. Early (37-<39), full (39-<41), and late (41-<42 weeks) term groups were defined by the American College of Obstetricians and Gynecologists. RESULTS: Of 399 infants, 136 (34.1%), 229 (57.4%), and 34 (8.5%) were born in the early, full, and late-term periods, respectively. Two hundred and seventy patients (67.7%) received medication-assisted treatment for opioid use disorder, and the baseline characteristics were similar in all the groups except for history of intranasal heroin use, positive urine toxicology screen for heroin or any opiates, and delivery indication (P<.05). The primary composite outcome occurred in 313 (78.4%) neonates, and 296 (74.2%) neonates had neonatal opioid withdrawal syndrome. More than half (219 [54.9%]) of opioid-exposed neonates were admitted to the neonatal intensive care unit, and 160 (40.1%) required pharmacologic neonatal opioid withdrawal syndrome treatment for a mean duration of almost 3 weeks (19.0±16.1 days). There were no significant differences in the primary composite outcome, incidence of neonatal opioid withdrawal syndrome, or other secondary outcomes (except birthweight) between neonates born in the early, full, or late-term periods. CONCLUSION: Although neonatal morbidity was frequent among opioid-exposed neonates, the incidence and severity of neonatal opioid withdrawal syndrome or other neonatal outcomes were not different between neonates delivered in the early, full, and late-term periods, suggesting that opioid-exposed infants may not benefit from early term delivery.
引用
- Sanusi A, Gray M, Xue Y, et al. Delivery timing for the opioid-exposed infant. Am J Obstet Gynecol MFM. 2022. PMID: 35977700. doi:10.1016/j.ajogmf.2022.100719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。